Company · CIK 0001501756 · SIC 2836 — Biological Products, (No Diagnostic Substances)
Adverum Biotechnologies, Inc. · ADVM
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 28, 2015 MForm 4 → | Apr 30, 6:51 pm EDT | Mehdi GasmiVP, Pharmaceutical Development | 1,000 | $2.75 | $2,750 | 8,000 | — | plan? |
| Apr 27, 2015 SForm 4 → | Apr 29, 5:47 pm EDT | Paul WachterDirector | 1,192 | $35.61 | $42,443 | 45,505 | −2.55% | plan? |
| Apr 23, 2015 SForm 4 → | Apr 23, 7:52 pm EDT | Steven Daniel SchwartzDirector | 16,875 | $38.62 | $651,665 | 436,181 | −3.72% | plan? |
| Apr 21, 2015 AForm 4 → | Apr 23, 5:02 pm EDT | Paul WachterDirector | 2,000 | — | — | 2,000 | — | plan? |
| Apr 21, 2015 AForm 4 → | Apr 23, 5:02 pm EDT | Steven Daniel SchwartzDirector | 2,000 | — | — | 453,056 | — | plan? |
| Apr 21, 2015 AForm 4 → | Apr 23, 5:01 pm EDT | Roman G. RubioSVP, Translational Medicine | 7,000 | — | — | 7,000 | — | plan? |
| Apr 21, 2015 AForm 4 → | Apr 23, 5:00 pm EDT | John Peter McLaughlinDirector | 2,000 | — | — | 2,000 | — | plan? |
| Apr 21, 2015 AForm 4 → | Apr 23, 4:59 pm EDT | Hans HullSVP, Business Operations | 8,000 | — | — | 11,320 | — | plan? |
| Apr 21, 2015 SForm 4 → | Apr 23, 4:58 pm EDT | Mehdi GasmiVP, Pharmaceutical Development | 1,000 | $39.21 | $39,211 | 0 | −100% | plan? |
| Apr 21, 2015 AMForm 4 → | Apr 23, 4:58 pm EDT | Mehdi GasmiVP, Pharmaceutical Development | 8,000 | $2.75 | $2,750 | 7,000 | — | plan? |
| Apr 21, 2015 AForm 4 → | Apr 23, 4:57 pm EDT | Thomas W. ChalbergChief Executive Officer, Director | 23,000 | — | — | 308,988 | — | plan? |
| Apr 21, 2015 AForm 4 → | Apr 23, 4:56 pm EDT | Mark S. BlumenkranzDirector | 2,000 | — | — | 597,989 | — | plan? |
| Apr 21, 2015 AForm 4 → | Apr 23, 4:55 pm EDT | Samuel B. BaroneChief Medical Officer | 7,000 | — | — | 7,000 | — | plan? |
| Apr 21, 2015 AForm 4 → | Apr 23, 4:53 pm EDT | Linda BainChief Financial Officer | 9,000 | — | — | 9,000 | — | plan? |
| Apr 20, 2015 SForm 4 → | Apr 21, 5:49 pm EDT | Paul WachterDirector | 1,192 | $40.19 | $47,910 | 46,697 | −2.49% | plan? |
| Apr 16, 2015 SForm 4 → | Apr 20, 5:37 pm EDT | Mark S. BlumenkranzDirector | 25,000 | $41.59 | $1,039,753 | 595,989 | −4.03% | plan? |
| Apr 14, 2015 SForm 4 → | Apr 15, 5:24 pm EDT | Mehdi GasmiVP, Pharmaceutical Development | 1,000 | $39.45 | $39,448 | 0 | −100% | plan? |
| Apr 14, 2015 MForm 4 → | Apr 15, 5:24 pm EDT | Mehdi GasmiVP, Pharmaceutical Development | 1,000 | $2.75 | $2,750 | 1,000 | — | plan? |
| Apr 13, 2015 SForm 4 → | Apr 15, 5:25 pm EDT | Zygtech, LLC10% Owner | 25,000 | $39.55 | $988,672 | 2,438,176 | −1.01% | plan? |
| Apr 13, 2015 SForm 4 → | Apr 15, 5:25 pm EDT | Paul WachterDirector | 1,192 | $39.34 | $46,896 | 47,889 | −2.43% | plan? |
| Apr 9, 2015 SForm 4 → | Apr 13, 4:47 pm EDT | Steven Daniel SchwartzDirector | 17,250 | $39.73 | $685,278 | 451,056 | −3.68% | plan? |
| Apr 7, 2015 SForm 4 → | Apr 8, 4:47 pm EDT | Mark S. BlumenkranzDirector | 28,000 | $38.72 | $1,084,209 | 11,531 | −70.8% | plan? |
| Apr 7, 2015 SForm 4 → | Apr 8, 4:32 pm EDT | Hans HullSVP, Business Operations | 27,500 | $38.60 | $1,061,573 | 3,320 | −89.2% | plan? |
| Apr 7, 2015 MForm 4 → | Apr 8, 4:32 pm EDT | Hans HullSVP, Business Operations | 27,500 | $0.19 | $5,225 | 30,820 | — | plan? |
| Apr 7, 2015 SForm 4 → | Apr 8, 4:29 pm EDT | Mehdi GasmiVP, Pharmaceutical Development | 9,000 | $38.60 | $347,425 | 0 | −100% | plan? |
| Apr 7, 2015 MForm 4 → | Apr 8, 4:29 pm EDT | Mehdi GasmiVP, Pharmaceutical Development | 9,000 | $2.75 | $24,750 | 9,000 | — | plan? |
| Jan 13, 2015 SForm 4 → | Jan 15, 5:00 pm EST | Zygtech, LLC10% Owner | 100,000 | $55.46 | $5,546,000 | 2,463,176 | −3.90% | plan? |
| Jan 13, 2015 SForm 4 → | Jan 15, 4:59 pm EST | Paul WachterDirector | 14,000 | $55.46 | $776,440 | 49,081 | −22.2% | plan? |
| Jan 13, 2015 SForm 4 → | Jan 15, 4:58 pm EST | Steven Daniel SchwartzDirector | 91,000 | $55.46 | $5,046,860 | 468,306 | −16.3% | plan? |
| Jan 13, 2015 SForm 4 → | Jan 15, 4:58 pm EST | Thomas W. ChalbergChief Executive Officer, Director | 85,000 | $55.46 | $4,714,100 | 285,988 | −22.9% | plan? |
| Jan 13, 2015 SForm 4 → | Jan 15, 4:57 pm EST | Mark S. BlumenkranzDirector | 100,000 | $55.46 | $5,546,000 | 645,989 | −13.4% | plan? |
| Dec 12, 2014 GMForm 4 → | Jan 14, 2015, 5:43 pm EST | Thomas W. ChalbergChief Executive Officer, Director | 1,239 | $0.21 | $87 | 413 | — | plan? late |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 14, 2019 AForm 4 → | Feb 19, 4:17 pm EST | Jennifer C. ChengGeneral Counsel | 80,000 | — | — | 80,000 | — | |
| Feb 14, 2019 AForm 4 → | Feb 19, 4:17 pm EST | Mehdi GasmiPresident and CSO | 225,000 | — | — | 225,000 | — | |
| Feb 14, 2019 AForm 4 → | Feb 19, 4:15 pm EST | Leone D PattersonCEO, CFO and Director, Director | 800,000 | — | — | 800,000 | — | |
| Oct 18, 2018 AForm 4 → | Oct 22, 4:17 pm EDT | Leone D PattersonPresident, CEO and CFO | 150,000 | — | — | 150,000 | — | |
| May 31, 2018 AForm 4 → | Jun 15, 4:38 pm EDT | Patrick MachadoDirector | 35,000 | — | — | 35,000 | — | late |
| May 31, 2018 AForm 4 → | Jun 15, 4:30 pm EDT | Richard N. SpiveyDirector | 35,000 | — | — | 35,000 | — | late |
| May 31, 2018 AForm 4 → | Jun 15, 4:28 pm EDT | Eric G CarterDirector | 35,000 | — | — | 35,000 | — | late |
| May 31, 2018 AForm 4 → | Jun 15, 4:27 pm EDT | Thomas WoiwodeDirector | 35,000 | — | — | 35,000 | — | late |
| May 31, 2018 AForm 4 → | Jun 15, 4:26 pm EDT | Mitchell H. FinerDirector | 35,000 | — | — | 35,000 | — | late |
| May 31, 2018 AForm 4 → | Jun 15, 4:25 pm EDT | Paul B ClevelandDirector | 35,000 | — | — | 35,000 | — | late |
| Feb 15, 2018 AForm 4 → | Feb 20, 7:19 pm EST | Patrick MachadoDirector | 10,000 | — | — | 10,000 | — | |
| Feb 15, 2018 AForm 4 → | Feb 20, 7:18 pm EST | Jennifer C. ChengGeneral Counsel | 114,000 | — | — | 114,000 | — | |
| Feb 15, 2018 AForm 4 → | Feb 20, 7:17 pm EST | Leone D PattersonChief Financial Officer | 160,000 | — | — | 160,000 | — | |
| Feb 15, 2018 AForm 4 → | Feb 20, 7:17 pm EST | Mehdi GasmiChief Science & Tech Officer | 160,000 | — | — | 160,000 | — | |
| Feb 15, 2018 AForm 4 → | Feb 20, 7:16 pm EST | Athena CountouriotisSVP, Chief Medical Officer | 160,000 | — | — | 160,000 | — | |
| Feb 15, 2018 AForm 4 → | Feb 20, 7:15 pm EST | Amber SalzmanPresident and CEO, Director | 478,000 | — | — | 478,000 | — | |
| Sep 7, 2017 AForm 4 → | Sep 8, 6:40 pm EDT | Eric G CarterDirector | 69,000 | — | — | 69,000 | — | |
| Jun 19, 2017 AForm 4 → | Jun 21, 6:11 pm EDT | Athena CountouriotisSVP, Chief Medical Officer | 213,000 | — | — | 213,000 | — | |
| Jun 12, 2017 AForm 4 → | Jun 14, 7:13 pm EDT | Mitchell H. FinerDirector | 33,602 | — | — | 33,602 | — | |
| Jun 12, 2017 AForm 4 → | Jun 14, 7:12 pm EDT | Richard N. SpiveyDirector | 33,602 | — | — | 33,602 | — | |
| Jun 12, 2017 AForm 4 → | Jun 14, 7:11 pm EDT | Thomas WoiwodeDirector | 33,602 | — | — | 33,602 | — | |
| Jun 12, 2017 AForm 4 → | Jun 14, 7:09 pm EDT | Paul B ClevelandChief Executive Officer, Director | 33,602 | — | — | 33,602 | — | |
| Jun 12, 2017 AForm 4 → | Jun 14, 7:07 pm EDT | Steven Daniel SchwartzDirector | 33,602 | — | — | 33,602 | — | |
| Jun 12, 2017 AForm 4 → | Jun 14, 7:04 pm EDT | Patrick MachadoDirector | 33,602 | — | — | 33,602 | — | |
| Apr 19, 2017 AForm 4 → | Apr 21, 4:34 pm EDT | Richard N. SpiveyDirector | 69,061 | — | — | 69,061 | — | |
| Mar 14, 2017 AForm 4 → | Mar 16, 7:19 pm EDT | Patrick MachadoDirector | 64,767 | — | — | 64,767 | — | |
| Feb 9, 2017 AForm 4 → | Feb 13, 5:47 pm EST | Amber SalzmanPresident and CEO, Director | 378,000 | — | — | 378,000 | — | |
| Feb 9, 2017 AForm 4 → | Feb 13, 5:43 pm EST | Leone D PattersonCFO | 116,000 | — | — | 116,000 | — | |
| Feb 9, 2017 AForm 4 → | Feb 13, 5:40 pm EST | Mehdi GasmiChief Science & Tech Officer | 181,000 | — | — | 181,000 | — | |
| Feb 9, 2017 AForm 4 → | Feb 13, 5:35 pm EST | Samuel B. BaroneSVP, Clinical Development | 84,000 | — | — | 84,000 | — | |
| Jun 17, 2016 AForm 4 → | Jun 21, 5:51 pm EDT | Samuel B. BaroneSVP, Clinical Development | 50,000 | — | — | 50,000 | — | |
| Jun 15, 2016 AForm 4 → | Jun 16, 7:26 pm EDT | Leone D PattersonCFO | 200,000 | — | — | 200,000 | — | |
| May 11, 2016 AForm 4 → | Jul 1, 6:18 pm EDT | Thomas WoiwodeDirector | 44,248 | — | — | 44,248 | — | late |
| May 11, 2016 AForm 4 → | Jul 1, 6:16 pm EDT | Mitchell H. FinerDirector | 44,248 | — | — | 44,248 | — | late |
| May 11, 2016 AForm 4 → | May 13, 5:52 pm EDT | Amber SalzmanPresident and COO, Director | 595,890 | — | — | 218,000 | — | |
| May 11, 2016 AForm 4 → | May 13, 5:48 pm EDT | Carlo RussoEVP and Chief Medical Officer | 781,991 | — | — | 66,000 | — | |
| May 11, 2016 AForm 4 → | May 13, 5:40 pm EDT | Paul B ClevelandChief Executive Officer, Director | 381,000 | — | — | 381,000 | — | |
| Feb 12, 2016 AForm 4 → | Feb 17, 5:42 pm EST | John Peter McLaughlinDirector | 11,905 | — | — | 11,905 | — | |
| Feb 12, 2016 AForm 4 → | Feb 17, 5:40 pm EST | Steven Daniel SchwartzDirector | 11,905 | — | — | 11,905 | — | |
| Feb 12, 2016 AForm 4 → | Feb 17, 5:37 pm EST | Mark S. BlumenkranzDirector | 11,905 | — | — | 11,905 | — | |
| Feb 12, 2016 AForm 4 → | Feb 17, 5:34 pm EST | Paul WachterDirector | 11,905 | — | — | 11,905 | — | |
| Feb 12, 2016 AForm 4 → | Feb 17, 5:33 pm EST | Mehdi GasmiChief Scientific Officer | 188,000 | — | — | 188,000 | — | |
| Feb 12, 2016 AForm 4 → | Feb 17, 5:31 pm EST | Roman G. RubioSVP, Translational Medicine | 75,000 | — | — | 75,000 | — | |
| Feb 12, 2016 AForm 4 → | Feb 17, 5:30 pm EST | Samuel B. BaroneChief Medical Officer | 75,000 | — | — | 75,000 | — | |
| Dec 9, 2015 AForm 4 → | Dec 11, 4:59 pm EST | Paul B ClevelandPresident and CEO, Director | 910,000 | — | — | 910,000 | — | |
| Jun 15, 2015 MForm 4 → | Jun 17, 8:33 pm EDT | Mehdi GasmiSVP,Pharmaceutical Development | 500 | — | — | 95,000 | — | |
| Jun 12, 2015 MForm 4 → | Jun 16, 6:25 pm EDT | Hans HullSVP, Business Operations | 8,300 | — | — | 12,200 | — | |
| Jun 12, 2015 MForm 4 → | Jun 15, 5:00 pm EDT | Linda BainChief Financial Officer | 3,500 | — | — | 233,000 | — | |
| Jun 8, 2015 MForm 4 → | Jun 10, 8:28 pm EDT | Mehdi GasmiVP, Pharmaceutical Development | 500 | — | — | 95,500 | — | |
| Jun 4, 2015 MForm 4 → | Jun 5, 5:59 pm EDT | Hans HullSVP, Business Operations | 2,000 | — | — | 20,500 | — | |
| May 28, 2015 MForm 4/A → | Jun 5, 8:00 pm EDT | Mehdi GasmiVP, Pharmaceutical Development | 500 | — | — | 96,000 | — | |
| May 28, 2015 MForm 4 → | May 29, 2:37 pm EDT | Mehdi GasmiVP, Pharmaceutical Development | 500 | — | — | 96,000 | — | amended |
| May 21, 2015 MForm 4 → | May 22, 4:36 pm EDT | Mehdi GasmiVP, Pharmaceutical Development | 500 | — | — | 96,500 | — | |
| May 14, 2015 MForm 4 → | May 15, 5:47 pm EDT | Mehdi GasmiVP, Pharmaceutical Development | 500 | — | — | 97,000 | — | |
| May 13, 2015 MForm 4 → | May 13, 7:15 pm EDT | Linda BainChief Financial Officer | 285 | — | — | 236,500 | — | |
| May 11, 2015 MForm 4 → | May 12, 5:03 pm EDT | Linda BainChief Financial Officer | 715 | — | — | 236,785 | — | |
| May 7, 2015 MForm 4 → | May 8, 7:09 pm EDT | Mehdi GasmiVP, Pharmaceutical Development | 500 | — | — | 97,500 | — | |
| May 4, 2015 MForm 4 → | May 6, 4:06 pm EDT | Hans HullSVP, Business Operations | 5,000 | — | — | 22,500 | — | |
| May 4, 2015 MForm 4 → | May 6, 4:06 pm EDT | Linda BainChief Financial Officer | 2,500 | — | — | 237,500 | — | |
| Apr 28, 2015 MForm 4 → | Apr 30, 6:51 pm EDT | Mehdi GasmiVP, Pharmaceutical Development | 1,000 | — | — | 98,000 | — | |
| Apr 21, 2015 AForm 4 → | Apr 23, 5:02 pm EDT | Paul WachterDirector | 7,000 | — | — | 7,000 | — | |
| Apr 21, 2015 AForm 4 → | Apr 23, 5:02 pm EDT | Steven Daniel SchwartzDirector | 7,000 | — | — | 7,000 | — | |
| Apr 21, 2015 AForm 4 → | Apr 23, 5:01 pm EDT | Roman G. RubioSVP, Translational Medicine | 20,000 | — | — | 20,000 | — | |
| Apr 21, 2015 AForm 4 → | Apr 23, 5:00 pm EDT | John Peter McLaughlinDirector | 7,000 | — | — | 7,000 | — | |
| Apr 21, 2015 AForm 4 → | Apr 23, 4:59 pm EDT | Hans HullSVP, Business Operations | 23,000 | — | — | 23,000 | — | |
| Apr 21, 2015 AMForm 4 → | Apr 23, 4:58 pm EDT | Mehdi GasmiVP, Pharmaceutical Development | 21,000 | — | — | 20,000 | — | |
| Apr 21, 2015 AForm 4 → | Apr 23, 4:57 pm EDT | Thomas W. ChalbergChief Executive Officer, Director | 67,000 | — | — | 67,000 | — | |
| Apr 21, 2015 AForm 4 → | Apr 23, 4:56 pm EDT | Mark S. BlumenkranzDirector | 7,000 | — | — | 7,000 | — | |
| Apr 21, 2015 AForm 4 → | Apr 23, 4:55 pm EDT | Samuel B. BaroneChief Medical Officer | 20,000 | — | — | 20,000 | — | |
| Apr 21, 2015 AForm 4 → | Apr 23, 4:53 pm EDT | Linda BainChief Financial Officer | 25,000 | — | — | 25,000 | — | |
| Apr 14, 2015 MForm 4 → | Apr 15, 5:24 pm EDT | Mehdi GasmiVP, Pharmaceutical Development | 1,000 | — | — | 100,000 | — | |
| Apr 7, 2015 MForm 4 → | Apr 8, 4:32 pm EDT | Hans HullSVP, Business Operations | 27,500 | — | — | 27,500 | — | |
| Apr 7, 2015 MForm 4 → | Apr 8, 4:29 pm EDT | Mehdi GasmiVP, Pharmaceutical Development | 9,000 | — | — | 101,000 | — | |
| Dec 12, 2014 MForm 4 → | Jan 14, 2015, 5:43 pm EST | Thomas W. ChalbergChief Executive Officer, Director | 413 | — | — | 159,587 | — | late |